"Receptors, LDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Receptors on the plasma membrane of nonhepatic cells that specifically bind LDL. The receptors are localized in specialized regions called coated pits. Hypercholesteremia is caused by an allelic genetic defect of three types: 1, receptors do not bind to LDL; 2, there is reduced binding of LDL; and 3, there is normal binding but no internalization of LDL. In consequence, entry of cholesterol esters into the cell is impaired and the intracellular feedback by cholesterol on 3-hydroxy-3-methylglutaryl CoA reductase is lacking.
| Descriptor ID |
D011973
|
| MeSH Number(s) |
D12.776.543.750.710.450
|
| Concept/Terms |
Receptors, LDL- Receptors, LDL
- LDL Receptors
- LDL Receptors, Lipoprotein
- Receptors, Lipoprotein LDL
- Lipoprotein LDL Receptors
- Low Density Lipoprotein Receptors
- Receptors, Lipoprotein, LDL
- Receptors, Low Density Lipoprotein
- LDL Receptor
- Receptor, LDL
- Low Density Lipoprotein Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptors, LDL".
Below are MeSH descriptors whose meaning is more specific than "Receptors, LDL".
This graph shows the total number of publications written about "Receptors, LDL" by people in this website by year, and whether "Receptors, LDL" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 3 | 0 | 3 |
| 1998 | 3 | 0 | 3 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 1 | 3 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 0 | 1 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, LDL" by people in Profiles.
-
Evolocumab in patients with homozygous familial hypercholesterolemia in India. J Clin Lipidol. 2021 Nov-Dec; 15(6):814-821.
-
Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program. Arterioscler Thromb Vasc Biol. 2020 11; 40(11):2747-2755.
-
Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020 08 20; 383(8):711-720.
-
Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations. PLoS One. 2020; 15(2):e0229098.
-
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):592-598.
-
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res. 2016 06; 57(6):1086-96.
-
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report. Arterioscler Thromb Vasc Biol. 2016 08; 36(8):1647-50.
-
Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. Atherosclerosis. 2016 May; 248:238-44.
-
The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation. 2015 Dec 01; 132(22):2167-92.
-
Familial hypercholesterolaemia: A global call to arms. Atherosclerosis. 2015 Nov; 243(1):257-9.